Russia
A pharma company, together with the AI lab of a bank, cut the step of designing antibody structures from about 3 years to 2 months. The lab confirmed the hypotheses, and the cycle from idea to validated structure became 3 times shorter (2024). Another company built a pipeline: the lab stage of molecule analysis takes weeks instead of 7–14 months. The company had 78 registered drugs at the end of 2024 and 32% more clinical trials. A third company, by its own estimate, halved development time and raised the share of successful candidates at least 2.5 times. The Kurchatov Institute found more than 100 genomic loci linked to stroke.
The world
A candidate molecule against pulmonary fibrosis, found with generative AI, passed phase IIa on 71 patients: at the highest dose, lung function rose by 98.4 ml on average, against a fall of 20.3 ml on placebo. According to the company, the path to the candidate took about 18 months instead of the usual 4.5 years (Nature Medicine, 2025). An open model for protein structure prediction: more than 200 million structures, more than 3 million researchers in 190 countries, the 2024 Nobel Prize, and more than 30% of the papers that use it deal with diseases.
The caveat
All the cases are about candidates and the steps before the clinic. A molecule becomes a drug only after clinical trials approved by Russia’s Ministry of Health (drug law 61-FZ) and registration; advertising of unregistered drugs is not allowed. Our area is called “molecule search”, not “drug creation”, and this page keeps the same line.
What we do
Reviews with sources. Computational experiments on open databases are in preparation: they will come out as research papers with methods and limits. We are looking for partners for lab testing. More on the research page.